JP2020511936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511936A5 JP2020511936A5 JP2019528908A JP2019528908A JP2020511936A5 JP 2020511936 A5 JP2020511936 A5 JP 2020511936A5 JP 2019528908 A JP2019528908 A JP 2019528908A JP 2019528908 A JP2019528908 A JP 2019528908A JP 2020511936 A5 JP2020511936 A5 JP 2020511936A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- acid sequence
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 108091008874 T cell receptors Proteins 0.000 claims 23
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100025178 DDB1- and CUL4-associated factor 4-like protein 2 Human genes 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 101000721255 Homo sapiens DDB1- and CUL4-associated factor 4-like protein 2 Proteins 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431580P | 2016-12-08 | 2016-12-08 | |
| DE102016123859.7A DE102016123859B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| US62/431,580 | 2016-12-08 | ||
| DE102016123859.7 | 2016-12-08 | ||
| PCT/EP2017/081893 WO2018104478A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511936A JP2020511936A (ja) | 2020-04-23 |
| JP2020511936A5 true JP2020511936A5 (enExample) | 2020-06-11 |
Family
ID=61167304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528908A Pending JP2020511936A (ja) | 2016-12-08 | 2017-12-07 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10527623B2 (enExample) |
| EP (1) | EP3551654A1 (enExample) |
| JP (1) | JP2020511936A (enExample) |
| KR (1) | KR20190086562A (enExample) |
| CN (1) | CN110036027A (enExample) |
| AU (1) | AU2017373815C1 (enExample) |
| BR (1) | BR112019010699A2 (enExample) |
| CA (1) | CA3045234A1 (enExample) |
| CR (1) | CR20190276A (enExample) |
| DE (1) | DE102016123859B3 (enExample) |
| MX (1) | MX2019006727A (enExample) |
| PE (1) | PE20191081A1 (enExample) |
| TW (1) | TW201828977A (enExample) |
| WO (1) | WO2018104478A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CN112236447B (zh) * | 2018-04-19 | 2023-10-20 | 得克萨斯州大学系统董事会 | 具有mage-b2特异性的t细胞受体及其用途 |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| PH12021553042A1 (en) | 2019-06-06 | 2023-09-11 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20220251235A1 (en) * | 2019-07-09 | 2022-08-11 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
| KR20220053575A (ko) * | 2019-08-01 | 2022-04-29 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 항체 결합 및 중화 항체 억제를 위한 조성물 및 방법 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| WO2021086991A1 (en) * | 2019-10-30 | 2021-05-06 | The Regents Of The University Of California | Methods of treating systemic lupus erythematosus |
| US20250243272A1 (en) * | 2019-11-08 | 2025-07-31 | Good T Cells, Inc. | Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| CN111624342A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| EP4453016A1 (en) * | 2021-12-21 | 2024-10-30 | Amgen Inc. | Dcaf4l2-specific t-cell receptors |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115216514A (zh) * | 2022-08-01 | 2022-10-21 | 中国科学技术大学 | Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用 |
| WO2024139780A1 (zh) * | 2022-12-26 | 2024-07-04 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 |
| WO2025024648A2 (en) * | 2023-07-25 | 2025-01-30 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting tp53 hotspot mutations and uses thereof |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP2660250B1 (en) | 2012-05-02 | 2018-11-14 | Deutsches Rheuma-Forschungszentrum Berlin | Tcr transgenic mouse model for immune disease |
| MX367279B (es) * | 2012-09-14 | 2019-08-13 | Us Health | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. |
| CN106103711A (zh) * | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| MX2017000646A (es) * | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| CN105506065A (zh) * | 2014-09-25 | 2016-04-20 | 上海人类基因组研究中心 | 肝癌基因检测方法、检测试剂盒及其应用 |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201520583D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
-
2016
- 2016-12-08 DE DE102016123859.7A patent/DE102016123859B3/de not_active Expired - Fee Related
-
2017
- 2017-12-07 MX MX2019006727A patent/MX2019006727A/es unknown
- 2017-12-07 EP EP17825768.9A patent/EP3551654A1/en not_active Withdrawn
- 2017-12-07 WO PCT/EP2017/081893 patent/WO2018104478A1/en not_active Ceased
- 2017-12-07 JP JP2019528908A patent/JP2020511936A/ja active Pending
- 2017-12-07 AU AU2017373815A patent/AU2017373815C1/en not_active Ceased
- 2017-12-07 BR BR112019010699A patent/BR112019010699A2/pt not_active IP Right Cessation
- 2017-12-07 CA CA3045234A patent/CA3045234A1/en not_active Abandoned
- 2017-12-07 CN CN201780075298.4A patent/CN110036027A/zh active Pending
- 2017-12-07 PE PE2019001096A patent/PE20191081A1/es unknown
- 2017-12-07 US US15/835,095 patent/US10527623B2/en not_active Expired - Fee Related
- 2017-12-07 KR KR1020197019008A patent/KR20190086562A/ko not_active Abandoned
- 2017-12-07 CR CR20190276A patent/CR20190276A/es unknown
- 2017-12-08 TW TW106143135A patent/TW201828977A/zh unknown
-
2018
- 2018-07-02 US US16/025,434 patent/US10725044B2/en not_active Expired - Fee Related
-
2020
- 2020-03-24 US US16/828,577 patent/US20200249233A1/en not_active Abandoned